Faropenem

( )-(5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furyl]-4-thia-1-acabicyclo[3.2.0]hept-2-en-2-carboxylsäure (IUPAC)

J01DI03

Colorless to brownish powder ( sodium hydrate )

Antibiotic

Template: Infobox chemical / molecular formula search available

Faropenem is an orally active beta -lactam antibiotic from the group of carbapenems. It was developed by Daiichi Pharmaceutical Asubio and 1997 approved in Japan for treatment of certain accordingly caused by susceptible strains of infectious diseases. In the U.S., a new drug application for Faropenem medoxomil failed for the treatment of sinusitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis, and uncomplicated skin infections at the inadequate proven efficacy. Faropenem pharmaceutically used in the form of its sodium salt or prodrug Faropenemmedoxomil.